Editor in Chief Dr KK Aggarwal, Padma Shri Awardee                                                                               Dated:24 November,2019

FDA approves new treatment for adults with partial-onset seizures

The U.S. Food and Drug Administration has approved XCOPRI (cenobamate tablets) to treat partial-onset seizures in adults. The safety and efficacy of XCOPRI to treat partial-onset seizures was established in two randomized, double-blind, placebo-controlled studies that enrolled 655 adults. “XCOPRI is a new option to treat adults with partial-onset seizures, which is an often difficult-to-control condition that can have a significant impact on patient quality of life,” said Billy Dunn, M.D., director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research… (FDA, November 21, 2019)

New drugs for heart failure

Heart failure and reduced ejection fraction (HFrEF) now has two new drugs


2.Sodium-glucose cotransporter 2 (SGLT2) inhibitors

In the DAPA-HF trial, treatment with the SGLT2 inhibitor dapagliflozin on top of standard HFrEF medicines, compared with standard medicines only, led to significantly improved risk not only for its clinical composite primary endpoint, but for mortality and a slew of other meaningful secondary outcomes.

The benefits are not mediated by the well-recognized antiglycemic effects of the SGLT2 inhibitor.

DAPA-HF entered more than 4700 patients with HFrEF without regard to their diabetes status.

Patients assigned to receive dapagliflozin on top of standard HFrEF medicines showed at least a one-fourth drop in risk of the clinical primary endpoint compared with those on standard medicines alone over a median of 18 months — also regardless of diabetes status. ....read more


Energy is the raw material of the universe.

Information is the organization of energy into reproducible patterns.

Consciousness is living information and energy (living energized information).

Consciousness is, therefore, intelligence. ....read more

Healthcare News Monitor

Standardization- need of the hour for Traditional Medicines in India : Dr R B Smarta
ET Healthworld

Traditional Medicines (TM) have great potential to grow in the country. Factors that would support this growth include increasing public awareness on the natural benefits of traditional medicines, who are shying away from chemical drugs, increased awareness on importance of prevention, growth in e-commerce and mobile internet, growth in disposable incomes etc. Time has come when chemical products through pharma and herbal products through Nutraceuticals, Ayurceuticals and phyto-pharmaceuticals will co-exist. In view of this, pharma companies have started their own division of traditional medicines. Modern medicines mitigate diseases directly whereas TM such as Ayurveda or Yunani builds upon the immunity of the body that fights the diseases. It is interesting to note that TMs operates on a similar definition of health as is accepted by WHO ‘Health is the state of complete physical, mental and social well being and not merely the absence of disease or infirmity.” Traditional medicines encompass the traditional methods of diagnosis (such as Nadi shastra); products derived from herbs, elements of nature and animals; body healing techniques based on faith and belief; acupuncture, magnetic therapies etc.

Lupin launches device to track metered-dose inhaler usage pattern in patients
moneycontrol – PTI

Drug maker Lupin on Friday said it has launched a device to track usage pattern of metered-dose inhalers (MDI) by patients suffering from chronic respiratory diseases. The device -- Adhero -- would help the patients track their MDI usage and facilitate improved adherence to therapy, Lupin Ltd said in a statement. The bluetooth-enabled device is attached to the top of a MDI and with built-in sensors helps track a patient's daily medication usage and consumption pattern. The inhalers are the preferred treatment option for managing chronic respiratory diseases such as Asthma and Chronic Obstructive Pulmonary Disease (COPD) in the country. However, it is estimated that nearly 45 per cent patients do not adhere to therapy in terms of filling, refilling prescriptions or maintaining prescribed medication schedule, which adversely impacts clinical outcomes.

Roche brings drug for small cell lung cancer to India
ET Healthworld – PTI

New Delhi: Drug firm Roche India on Thursday said it has launched Atezolizumab used for the treatment of small cell lung cancer in India after getting nod from Drugs Controller General of India. "Atezolizumab is the first cancer immunotherapy to receive an approval in India for the first line treatment of extensive-stage small cell lung cancer (ES-SCLC) when given in combination with chemotherapy," Roche India said in a statement. The cancer immunotherapy harnesses the person's immune system to combat cancer more effectively for better results, it added. "Roche is committed to bring to India all the innovations being developed in its pipeline, to benefit patients," Lara Bezerra, chief purpose officer at Roche Products (India) said. Launching Atezolizumab is an important step for small cell lung cancer patients in India, she added.

Cholesterol drugs could reduce risk of lethal prostate cancer in men by 24%, study says
The Print- Mohana Basu

Statins, a type of drug used to lower blood cholesterol, could reduce the risk of a lethal form of prostate cancer in men, a study led by Queen’s University Belfast suggests. Statins reduce the risk of heart diseases and earlier researches have suggested that they could have a role in slowing down the growth of different types of cancers. The new study, published in the journal Clinical Cancer Research Friday, specifically looked at the effect of the drugs on prostate cancer. The researchers — from Queen’s, Trinity College Dublin and Harvard Cancer Center — stated that men who had taken statin had a 24 per cent lower risk of developing a lethal type of prostate cancer. However, this is limited to the lethal form of the disease only. According to the study, there were no differences in the overall rates of prostate cancer among men who were prescribed the medicine. A large group of men were monitored over 24 years “Some prostate cancers are slow-growing and will not affect the man over the course of his lifetime, but others are aggressive and often deadly,” said Emma Allott, a researcher from the Queen’s University Belfast. “My work is to understand the biology driving these different types of prostate cancer in order to reduce the number of men who develop this lethal form of the disease,” she said.